Instylla, Inc.

New Capabilities

FDA-approval holder and US commercial seller of Embrace

The FDA on October 29 approved Instylla's Embrace hydrogel embolic system for a second indication: stopping peripheral arterial bleeds in vessels up to 6 millimeters. It is the first liquid embolic cleared for both arterial bleeding and hypervascular tumor embolization, and it is on the US market now.

Updated Nov 1